Weekly News Round-up – 14/2/20

The U.S. Institute for Clinical and Economic Review’s (ICER’s) methods could see legal challenges in the near future, a think tank has warned, due to discrimination against disabled individuals. In other news, Novartis’ rare lung cancer drug capmatinib will be...

2 weeks ago
Oncology,Bioprocess,Clinical Development,Weekly Roundups,Biology

Weekly News Round-up – 14/2/20

The U.S. Institute for Clinical and Economic Review’s (ICER’s) methods could see legal challenges in the near future, a think tank has warned, due to discrimination against disabled individuals. In other news, Novartis’ rare lung cancer drug capmatinib will be...

2 weeks ago

The Changing Role of the Blockbuster Drug

There are few pharmaceutical companies not seeking the next big "blockbuster", a market drug earning revenue over $1 billion. These big-name products, which include Keytruda and Lipitor, are well-marketed and broadly-effective, often across several illnesses. For years scientists have worked...

2 weeks ago
Oncology,R&D,Biology,News

The Changing Role of the Blockbuster Drug

There are few pharmaceutical companies not seeking the next big "blockbuster", a market drug earning revenue over $1 billion. These big-name products, which include Keytruda and Lipitor, are well-marketed and broadly-effective, often across several illnesses. For years scientists have worked...

2 weeks ago

Weekly News Round-up – 17/1/20

The week passed fairly uneventfully this time, with the baffling politics and shocking events of the new decade struggling to get started. Instead, research from Scottish universities indicated a link between a type of common gut bacteria and Parkinson's; a...

1 month ago
Oncology,Weekly Roundups,Biology

Weekly News Round-up – 17/1/20

The week passed fairly uneventfully this time, with the baffling politics and shocking events of the new decade struggling to get started. Instead, research from Scottish universities indicated a link between a type of common gut bacteria and Parkinson's; a...

1 month ago

The Future of Organ-on-a-Chip

Dozens of solutions have been suggested to lessen the crisis that has been hitting pharma R&D recently. Over the last decade, the cost of creating drugs has skyrocketed even as the amount of new medicines reaching market is steadily declining....

2 months ago
Oncology,R&D,Biology,News

The Future of Organ-on-a-Chip

Dozens of solutions have been suggested to lessen the crisis that has been hitting pharma R&D recently. Over the last decade, the cost of creating drugs has skyrocketed even as the amount of new medicines reaching market is steadily declining....

2 months ago

Cancer Drugs Could be Hitting Wrong Targets

Current cancer drugs may be hitting the wrong protein targets, a study has found, giving a possible explanation for the low success rates of those drugs during their early stages.  The study, recently published in Science Translational Medicine journal and...

6 months ago
Oncology,Biology,News

Cancer Drugs Could be Hitting Wrong Targets

Current cancer drugs may be hitting the wrong protein targets, a study has found, giving a possible explanation for the low success rates of those drugs during their early stages.  The study, recently published in Science Translational Medicine journal and...

6 months ago